Swiss Medica Announces Vice President in Charge of Anti-Depression Biohealth Solutions Division

TORONTO, Apr 13, 2005 (BUSINESS WIRE) -- Swiss Medica (SWME) is pleased to announce Wendy Kramer as Vice President in charge of the Company's newly acquired Anti-Depression BioHealth Solutions division. Ms. Kramer previously held positions at nationally recognized pharmaceutical companies, including Allergan, Inc., Mead Johnson Laboratories and Warner Lambert/Parke Davis. Her work as a chemist for Parke Davis was published in the Journal of Medicinal Chemistry and the Journal of Natural Products. Ms. Kramer made her mark at Interneutria, Inc., where she co-founded Walden Laboratories, and served as Vice President of Sales and Marketing.

"We are delighted that Wendy Kramer will head Swiss Medica's new division," said Swiss Medica's Chief Executive Officer, Raghu Kilambi. "Ms. Kramer brings a wealth of sales and marketing experience to her new position, where she will oversee the launch and distribution of a line of all natural, nutritional products for various problems associated with mood and appetite disturbances."

Ms. Kramer is responsible for generating over $25 million in new business for a number of startup and corporate operations over the past decade. As a consultant for sales, marketing and retail distribution, some of her most recent clients include Talking Rx, Puronyx Inc, and Prolac Inc. Prior to her consulting business, Ms. Kramer was Vice President of Marketing, North America, for Bulmers America, Inc., a $750 million UK-based alcoholic beverage business. During her tenure at Bulmers, she helped drive sales from $32M to $46M through unique and synergistic marketing programs.

Ms. Kramer holds a Bachelor of Science in Chemistry from Pennsylvania State University and a Masters Degree from Eastern Michigan University.

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at and

Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals in the United States, Canada and in Europe. O24 is widely available throughout Canada in leading pharmacies and natural food stores. It is currently sold in an increasing number of pharmacies throughout the United States. Customers can also visit, for ordering details and store locators for the nearest pharmacy.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.